Literature DB >> 11607885

Impairment of CYP3A4 capacity in patients receiving danazol therapy: examination on oxidative cortisol metabolism.

H Konishi1, A Takenaka, T Minouchi, A Yamaji.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11607885     DOI： 10.1055/s-2001-17912

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN： 0018-5043            Impact factor:   2.936


× No keyword cloud information.
  4 in total

1.  Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo.

Authors:  C-C Peng; I Templeton; K E Thummel; C Davis; K L Kunze; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2011-04-13       Impact factor: 6.875

2.  Rhadbomyolysis associated with co-administration of danazol and lovastatin.

Authors:  Sahil Khanna; William C Mundell
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

Review 3.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

4.  Effects of growth hormone deficiency and rhGH replacement therapy on the 6beta-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children.

Authors:  Blanca Sinués; Esteban Mayayo; Ana Fanlo; Esteban Mayayo; María L Bernal; Pilar Bocos; Elena Bello; Jose I Labarta; Angel Ferrández-Longás
Journal:  Eur J Clin Pharmacol       Date:  2004-09-07       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.